Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Mimedx (MDXG) over the last 15 years, with Q3 2025 value amounting to $2.0 million.

  • Mimedx's Change in Accured Expenses fell 3994.71% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 25032.26%. This contributed to the annual value of $2.9 million for FY2024, which is 5833.79% up from last year.
  • As of Q3 2025, Mimedx's Change in Accured Expenses stood at $2.0 million, which was down 3994.71% from $7.6 million recorded in Q2 2025.
  • Mimedx's Change in Accured Expenses' 5-year high stood at $8.0 million during Q3 2022, with a 5-year trough of -$11.4 million in Q2 2021.
  • For the 5-year period, Mimedx's Change in Accured Expenses averaged around -$412368.4, with its median value being -$269000.0 (2024).
  • As far as peak fluctuations go, Mimedx's Change in Accured Expenses tumbled by 25694.44% in 2021, and later soared by 292565.06% in 2025.
  • Mimedx's Change in Accured Expenses (Quarter) stood at -$3.7 million in 2021, then soared by 117.57% to $655000.0 in 2022, then surged by 525.5% to $4.1 million in 2023, then rose by 2.59% to $4.2 million in 2024, then tumbled by 51.39% to $2.0 million in 2025.
  • Its Change in Accured Expenses stands at $2.0 million for Q3 2025, versus $7.6 million for Q2 2025 and -$4.1 million for Q1 2025.